48,868
edits
Difference between revisions of "Urothelial carcinoma in situ"
Jump to navigation
Jump to search
m
Urothelial carcinoma in situ (view source)
Revision as of 19:04, 8 January 2014
, 19:04, 8 January 2014→Sign out
(→IHC) |
m (→Sign out) |
||
| Line 59: | Line 59: | ||
URINARY BLADDER LESION ("TUMOUR"), TRANSURETHRAL RESECTION URINARY BLADDER TUMOUR (TURBT): | URINARY BLADDER LESION ("TUMOUR"), TRANSURETHRAL RESECTION URINARY BLADDER TUMOUR (TURBT): | ||
- UROTHELIAL CARCINOMA IN SITU. | - UROTHELIAL CARCINOMA IN SITU. | ||
- MUSCULARIS PROPRIA PRESENT. | - BENIGN MUSCULARIS PROPRIA PRESENT. | ||
</pre> | |||
<pre> | |||
URINARY BLADDER, RANDOM BIOPSIES: | |||
- UROTHELIAL CARCINOMA IN SITU, SEE COMMENT. | |||
-- NO EVIDENCE OF LAMINA PROPRIA INVASION. | |||
- CHRONIC INFLAMMATION, MILD. | |||
- BENIGN MUSCULARIS PROPRIA PRESENT. | |||
COMMENT: | |||
A CK20 immunostain marks the full thickness of the urothelium in atypical areas. A p53 | |||
immunostain moderately marks up to 20% of atypical cells focally. A Ki-67 immunostain | |||
marks 20-50% of the cells in the atypical areas. | |||
</pre> | </pre> | ||